Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition

Walter Mihatsch; Christian Braegger; Jiri Bronsky; Cristina Campoy; Magnus Domellöf; Mary Fewtrell; Nataša Fidler Mis; Iva Hojsak; Jessie M Hulst; Flavia Indrio; Alexandre Lapillonne; Christian Mølgaard; Nick Embleton; Johannes B van Goudoever; ESPGHAN Committee on Nutrition

doi:10.1097/MPG.0000000000001232

Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition

Walter Mihatsch, Christian Braegger, Jiri Bronsky, Cristina Campoy, Magnus Domellöf, Mary Fewtrell, Nataša Fidler Mis, Iva Hojsak, Jessie M Hulst, Flavia Indrio, Alexandre Lapillonne, Christian Mølgaard, Nick Embleton, Johannes B van Goudoever, ESPGHAN Committee on Nutrition

Ernæring og Sundhed hos børn og voksne

36 Citationer (Scopus)

Abstract

Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K 1 by intramuscular injection at birth; or 3×2 mg vitamin K 1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K 1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K 1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.

Originalsprog	Engelsk
Tidsskrift	Journal of Pediatric Gastroenterology and Nutrition
Vol/bind	63
Udgave nummer	1
Sider (fra-til)	123-129
Antal sider	7
ISSN	0277-2116
DOI	https://doi.org/10.1097/MPG.0000000000001232
Status	Udgivet - 1 jul. 2016

Adgang til dokumentet

10.1097/MPG.0000000000001232

Citationsformater

Mihatsch, W., Braegger, C., Bronsky, J., Campoy, C., Domellöf, M., Fewtrell, M., Mis, N. F., Hojsak, I., Hulst, J. M., Indrio, F., Lapillonne, A., Mølgaard, C., Embleton, N., van Goudoever, J. B., & ESPGHAN Committee on Nutrition (2016). Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition. Journal of Pediatric Gastroenterology and Nutrition, 63(1), 123-129. https://doi.org/10.1097/MPG.0000000000001232

Mihatsch, W, Braegger, C, Bronsky, J, Campoy, C, Domellöf, M, Fewtrell, M, Mis, NF, Hojsak, I, Hulst, JM, Indrio, F, Lapillonne, A, Mølgaard, C, Embleton, N, van Goudoever, JB & ESPGHAN Committee on Nutrition 2016, 'Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition', Journal of Pediatric Gastroenterology and Nutrition, bind 63, nr. 1, s. 123-129. https://doi.org/10.1097/MPG.0000000000001232

@article{047eef731ac34b24ad1e889e986583dd,

title = "Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition",

abstract = "Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K 1 by intramuscular injection at birth; or 3×2 mg vitamin K 1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K 1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K 1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.",

author = "Walter Mihatsch and Christian Braegger and Jiri Bronsky and Cristina Campoy and Magnus Domell{\"o}f and Mary Fewtrell and Mis, {Nata{\v s}a Fidler} and Iva Hojsak and Hulst, {Jessie M} and Flavia Indrio and Alexandre Lapillonne and Christian M{\o}lgaard and Nick Embleton and {van Goudoever}, {Johannes B} and {ESPGHAN Committee on Nutrition}",

note = "CURIS 2016 NEXS 185",

year = "2016",

month = jul,

day = "1",

doi = "10.1097/MPG.0000000000001232",

language = "English",

volume = "63",

pages = "123--129",

journal = "Journal of Pediatric Gastroenterology and Nutrition",

issn = "0277-2116",

publisher = "Lippincott Williams & Wilkins",

number = "1",

}

TY - JOUR

T1 - Prevention of vitamin K deficiency bleeding in newborn infants

T2 - a position paper by the ESPGHAN Committee on Nutrition

AU - Mihatsch, Walter

AU - Braegger, Christian

AU - Bronsky, Jiri

AU - Campoy, Cristina

AU - Domellöf, Magnus

AU - Fewtrell, Mary

AU - Mis, Nataša Fidler

AU - Hojsak, Iva

AU - Hulst, Jessie M

AU - Indrio, Flavia

AU - Lapillonne, Alexandre

AU - Mølgaard, Christian

AU - Embleton, Nick

AU - van Goudoever, Johannes B

AU - ESPGHAN Committee on Nutrition

N1 - CURIS 2016 NEXS 185

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K 1 by intramuscular injection at birth; or 3×2 mg vitamin K 1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K 1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K 1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.

AB - Vitamin K deficiency bleeding (VKDB) due to physiologically low vitamin K plasma concentrations is a serious risk for newborn and young infants and can be largely prevented by adequate vitamin K supplementation. The aim of this position paper is to define the condition, describe the prevalence, discuss current prophylaxis practices and outcomes, and to provide recommendations for the prevention of VKDB in healthy term newborns and infants. All newborn infants should receive vitamin K prophylaxis and the date, dose, and mode of administration should be documented. Parental refusal of vitamin K prophylaxis after adequate information is provided should be recorded especially because of the risk of late VKDB. Healthy newborn infants should either receive 1 mg of vitamin K 1 by intramuscular injection at birth; or 3×2 mg vitamin K 1 orally at birth, at 4 to 6 days and at 4 to 6 weeks; or 2 mg vitamin K 1 orally at birth, and a weekly dose of 1 mg orally for 3 months. Intramuscular application is the preferred route for efficiency and reliability of administration. The success of an oral policy depends on compliance with the protocol and this may vary between populations and healthcare settings. If the infant vomits or regurgitates the formulation within 1 hour of administration, repeating the oral dose may be appropriate. The oral route is not appropriate for preterm infants and for newborns who have cholestasis or impaired intestinal absorption or are too unwell to take oral vitamin K 1, or those whose mothers have taken medications that interfere with vitamin K metabolism. Parents who receive prenatal education about the importance of vitamin K prophylaxis may be more likely to comply with local procedures.

U2 - 10.1097/MPG.0000000000001232

DO - 10.1097/MPG.0000000000001232

M3 - Journal article

C2 - 27050049

SN - 0277-2116

VL - 63

SP - 123

EP - 129

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

IS - 1

ER -

Prevention of vitamin K deficiency bleeding in newborn infants: a position paper by the ESPGHAN Committee on Nutrition

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater